Platform
Discovering, developing, and manufacturing next generation live biotherapeutics
Our state-of-the-art platform enables an unprecedented understanding of host-microbiome interaction and provides an efficient approach to drug discovery.
-
Mechanism
Visualization of host-microbiome interaction in situ
-
Manufacturing
Reproducible large-scale manufacturing of complex consortia
-
Complexity
Formulating live biotherapeutics that optimize healthy human-gut microbiome
A novel approach, from microbiome profiling to high-throughput drug manufacturing.
A platform for discovering, developing, and manufacturing next-generation live biotherapeutics takes advantage of our foundational understanding of the microbiome, addressing all FDA requirements and accelerating critical steps along the drug development pathway.
HiPR-FISH Technology
Mapping host-microbiome interactions in situ at high resolution & multiplexity
We simultaneously identify host-cell transcripts and microbial taxonomy. By profiling host-microbiome interaction in situ, we can gain an unprecedented understanding of the microbiome for novel therapeutic development.
ACT™ Manufacturing: Anaerobic Co-culture Technology
Manufacturing consortia from purified cell lines
We co-culture communities of isolated strains at an industrial scale with our state-of-the-art production technology.
Platform Partnerships
We work with partners to better understand the microbiome and its role in disease and drug candidates.
We have a vast partnership network made up of some of the top biotechnology and pharmaceutical companies in the scientific community.
Our pipeline enables rapid screening of several drug candidates for different diseases to benefit patients as soon as possible.